Grace Therapeutics, Inc. (GRCE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $38.08M
Last updated: Nov 17, 2026 at 11:04 AM ET
Grace Therapeutics, Inc. (GRCE) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Grace Therapeutics reported EPS of -$0.11. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GRCE's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 30 quarters below that had an estimate, GRCE beat 19 and missed 11. The widest gap in the table came in the quarter ended Mar 31, 2021, when EPS landed 500.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | -$0.21 | -$0.21 - -$0.21 | N/A | N/A | N/A | 1 | 0 up, 1 down | Nov 12, 2026 |
| Jun 30, 2026 | -$0.91 | -$0.18 | -$0.18 - -$0.18 | -405.56% | Miss | N/A | 1 | 1 up, 0 down | Aug 13, 2026 |
| Mar 31, 2026 | -$0.08 | -$0.20 | N/A | +60.00% | Beat | -260.0% | 1 | 1 up, 0 down | Jun 18, 2026 |
| Dec 31, 2025 | -$0.19 | -$0.39 | -$0.39 - -$0.39 | +51.28% | Beat | N/A | 1 | 0 up, 1 down | Feb 12, 2026 |
| Sep 30, 2025 | -$0.08 | -$0.34 | -$0.34 - -$0.34 | +76.47% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2025 |
| Jun 30, 2025 | -$0.29 | -$0.31 | N/A | +6.45% | Beat | N/A | 1 | 1 up, 0 down | Aug 12, 2025 |
| Mar 31, 2025 | $0.05 | -$0.40 | -$0.40 - -$0.28 | +112.55% | Beat | N/A | 3 | 1 up, 0 down | Jun 23, 2025 |
| Dec 31, 2024 | -$0.51 | -$0.46 | N/A | -11.67% | Miss | N/A | N/A | N/A | Feb 13, 2025 |
| Sep 30, 2024 | -$0.42 | -$0.50 | N/A | +16.79% | Beat | N/A | N/A | N/A | Nov 13, 2024 |
| Jun 30, 2024 | -$0.33 | -$0.36 | N/A | +8.33% | Beat | N/A | N/A | N/A | Aug 9, 2024 |
| Mar 31, 2024 | -$0.36 | -$0.47 | N/A | +24.13% | Beat | N/A | N/A | N/A | Jun 21, 2024 |
| Dec 31, 2023 | -$0.28 | -$0.31 | N/A | +9.68% | Beat | N/A | N/A | N/A | Feb 12, 2024 |
| Sep 30, 2023 | -$0.31 | -$0.35 | N/A | +11.43% | Beat | N/A | N/A | N/A | Nov 13, 2023 |
| Jun 30, 2023 | -$0.48 | -$0.37 | N/A | -29.73% | Miss | N/A | N/A | N/A | Aug 11, 2023 |
| Mar 31, 2023 | -$0.65 | -$0.14 | N/A | -364.29% | Miss | N/A | N/A | N/A | Jun 23, 2023 |
| Dec 31, 2022 | -$0.72 | -$1.01 | N/A | +28.71% | Beat | N/A | N/A | N/A | Feb 14, 2023 |
| Sep 30, 2022 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2022 |
| Jun 30, 2022 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 11, 2022 |
| Mar 31, 2022 | -$0.31 | -$1.00 | N/A | +69.00% | Beat | N/A | N/A | N/A | Jun 21, 2022 |
| Dec 31, 2021 | -$0.69 | -$0.62 | N/A | -11.29% | Miss | N/A | N/A | N/A | Feb 14, 2022 |
| Sep 30, 2021 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2021 |
| Jun 30, 2021 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 12, 2021 |
| Mar 31, 2021 | -$0.24 | -$0.04 | N/A | -500.00% | Miss | -209.1% | N/A | N/A | Jun 22, 2021 |
| Dec 31, 2020 | -$1.83 | -$2.50 | N/A | +26.80% | Beat | N/A | N/A | N/A | Feb 9, 2021 |
| Sep 30, 2020 | -$3.77 | -$3.17 | N/A | -18.93% | Miss | N/A | N/A | N/A | Nov 16, 2020 |
| Jun 30, 2020 | -$3.17 | -$3.89 | N/A | +18.51% | Beat | N/A | N/A | N/A | Aug 13, 2020 |
| Mar 31, 2020 | $0.22 | -$0.09 | N/A | +344.44% | Beat | N/A | N/A | N/A | Jun 29, 2020 |
| Dec 31, 2019 | -$8.64 | -$4.59 | N/A | -88.24% | Miss | N/A | N/A | N/A | Feb 14, 2020 |
| Sep 30, 2019 | -$16.32 | -$5.28 | N/A | -209.09% | Miss | N/A | N/A | N/A | Nov 13, 2019 |
| Jun 30, 2019 | -$7.20 | -$8.09 | N/A | +11.00% | Beat | N/A | N/A | N/A | Aug 14, 2019 |
| Mar 31, 2019 | -$0.02 | -$0.11 | N/A | +79.27% | Beat | N/A | N/A | N/A | Jun 26, 2019 |
| Dec 31, 2018 | -$3.36 | -$4.80 | N/A | +30.00% | Beat | N/A | N/A | N/A | Feb 14, 2019 |
| Sep 30, 2018 | -$29.76 | -$6.72 | N/A | -342.86% | Miss | N/A | N/A | N/A | Nov 14, 2018 |
| Jun 30, 2018 | -$11.04 | -$12.96 | N/A | +14.81% | Beat | N/A | N/A | N/A | Aug 14, 2018 |
| Mar 31, 2018 | -$12.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2018 |
| Dec 31, 2017 | -$19.20 | -$13.44 | N/A | -42.86% | Miss | N/A | N/A | N/A | Mar 31, 2018 |
| Sep 30, 2017 | -$11.71 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 |
| Jun 30, 2017 | -$6.74 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 15, 2017 |
| Dec 31, 2016 | -$8.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jan 13, 2017 |
| Sep 30, 2016 | -$8.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 30, 2016 |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was -$0.64, after -$1.21 the year before. It was -$21.58 for the year ended Mar 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | -$0.64 | N/A |
| Mar 31, 2025 | -$1.21 | N/A |
| Mar 31, 2024 | -$1.43 | N/A |
| Mar 31, 2023 | -$1.58 | N/A |
| Mar 31, 2022 | -$1.11 | N/A |
| Mar 31, 2021 | -$9.01 | N/A |
| Mar 31, 2020 | -$31.94 | N/A |
| Mar 31, 2019 | -$44.18 | N/A |
| Mar 31, 2018 | -$76.82 | N/A |
| Mar 31, 2016 | -$21.58 | N/A |
Frequently Asked Questions About GRCE
What EPS do analysts expect from GRCE next quarter?
The consensus EPS estimate for Grace Therapeutics for the quarter ending Dec 31, 2026 is -$0.21 from 1 analyst, with estimates from -$0.21 to -$0.21.
How often does GRCE beat earnings estimates?
Grace Therapeutics beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of -11.71%.
GRCE pages: Overview, Earnings, Forecast, Financials, Competitors